藍黛科技(002765.SZ):晟方投資方面減持0.3598%股份 合計持股降至5%以下
格隆匯11月4日丨藍黛科技(002765.SZ)公佈,2021年11月4日,公司收到持股5%以上股東暨一致行動人晟方投資、中遠智投、潘尚鋒、駱賽枝、陳海君、吳欽益、項延灶(統稱“晟方投資及一致行動人”)出具的《簡式權益變動報吿書》
晟方投資及一致行動人於2021年11月2日-11月3日通過集中競價、大宗交易合計減持公司股份206.94萬股,佔公司總股本的0.3598%。此次變動後,晟方投資及一致行動人合計持有公司股份2875.8204萬股,佔公司總股本的4.9999%,不再是公司持股5%以上股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.